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Abstract Earlier we reported that allelic variation in the 
gene coding for apolipoprotein (apoE) is a significant pre- 
dictor of  variation in the risk of  coronary heart disease 
(CHD) death in a longitudinal study of elderly Finnish 
men. Here we address the question: which of the apoE geno- 
types confers the risk information in these men, and whether 
such information persists after other CHD risk factors are 
considered? We followed two cohorts of elderly Finnish 
men aged 65 to 84 years, one in Eastern (n = 281) and the 
other in the Southwestern (n = 344) Finland for 5 years 
during which 26 (9.3%) of  the men from the Eastern co- 
hort and 40 (11.6%) of the men in the Southwestern co- 
hort died from CHD. Baseline high density lipoprotein 
(HDL) cholesterol and (HDL cholesterol) 2 in the Eastern 
cohort and age, and total and HDL cholesterol and smok- 
ing status in the Southwestern cohort were significant pre- 
dictors of CHD death (P < 0.05). The apoE genotypes were 
significant predictors in the Southwestern cohort at P = 0.02 
and in the Eastern cohort at P = 0.18. In multivariable 
models, information about apoE genotypes improved the 
prediction at P = 0.10 level of statistical significance in both 
cohorts. When genotypes were considered separately, the 
e2/4 combined with the e4/4 in the Eastern cohort (odds 
ratio = 7.69, 95% CI = 1.67-35.52) and the ~3/4 in the 
Southwestern cohort (odds ratio = 2.44, 95% CI = 1.16- 
5.10) had sigificanctly greater odds of CHD death com- 
pared to the common ~3/3 genotype. We conclude that 
apoE genotypes confer risk information about CHD death 
in two cohorts of elderly Finnish men in a longitudinal 
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study, and this information persists after adjustment for 
other CHD risk factors. Because different genotypes were 
predictors in these two cohorts, we further conclude that 
the utility of a particular genotype as a predictor of  CHD 
death in other populations may depend on the distribution 
of risk factor profiles at baseline, geographically defined 
environmental exposures, the CHD mortality history, and 
the evolutionary history of background genotypes in the 
population considered. 
Introduction 
Epidemiological and clinical studies have revealed the in- 
volvement of  a large number of  biochemical and physio- 
logical traits in the initiation, progression, and clinical 
manifestation of coronary heart disease (CHD). These in- 
clude quantitative measures of  lipid metabolism, glucose 
tolerance, blood pressure, and hemostasis (Badimon et al. 
1993; Dawber 1980; Gordon and Kannel 1982). About 50% 
of CHD cases can be predicted from knowledge about levels 
of known risk factor traits (Gordon and Kannel 1982). 
Measurements of  genetic variation at the DNA and 
protein-product levels are expected to improve our ability 
to predict CHD. Genotypes may be indicators of  risk be- 
cause of effects on (1) the phenotypic distributions of  
multiple biochemical or physiological risk factor traits 
(Kaprio et al. 1991), some of which may be inaccessible 
or difficult to measure in vivo, and (2) because utility of 
risk factor information may be genotype dependent (Reilly 
et al. 1991, 1994). Furthermore, genotypes also have the 
potential to predict how individuals will respond to alter- 
ations in the environment defined by diet, exedrcise, 
smoking, gender, and drug therapy (M~intt~iri et al. 1991; 
Nestruck et al. 1987), or to biological changes associated 
with aging (Davignon et al. 1989; Haviland et al. 1995). 
The common alleles, ~2, ~3 and ~4, of the gene coding 
for apolipoprotein E (apoE) are hypothesized to confer 
risk information because they are associated with in- 
terindividual variation in plasma lipid levels in healthy 
(Haviland et al. 1995; Kaprio et al. 199i; Xhignesse et al. 
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1991) and  d i s ea sed  popu l a t i ons  ( D a v i g n o n  et  al. 1988; Fer-  
r i~res  et  al. 1994;  S i n g  a n d  M o l l  1989) .  T h i s  h y p o t h e s i s  is 
s u p p o r t e d  b y  f i n d i n g s  t ha t  the  r e l a t i ve  ~4 a l l e le  f r e q u e n c y  
is e l e v a t e d  in h i g h  r i sk  p o p u l a t i o n s  ( D a v i g n o n  et  al. 1989;  
G e r d e s  et  al.  1992)  a n d  a m o n g  t h o s e  w i t h  C H D  in m o s t  
c r o s s - s e c t i o n a l  s tud ie s  ( D a v i g n o n  1993;  F e r r i b r e s  et  al. 
1994;  K u u s i  e t  al. 1989;  N i e m i n e n  et al. 1992;  W i l s o n  et 
al. 1994) .  R e c e n t l y  we  h a v e  r e p o r t e d  tha t  the  r e l a t i ve  f re-  
q u e n c y  o f  e 4  was  i n c r e a s e d  a m o n g  e l d e r l y  m e n  w h o  d i e d  
f r o m  C H D  d u r i n g  a 5 - y e a r  f o l l o w - u p  (Steng&rd et al. 
1995) .  
In the  s t u d y  r e p o r t e d  he re  w e  a s k e d  w h i c h  o f  the  a p o E  
g e n o t y p e s  c o n f e r s  i n f o r m a t i o n  a b o u t  r i sk  o f  C H D  d e a t h  
d u r i n g  a 5 - y e a r  f o l l o w - u p  o f  two  c o h o r t s  o f  F i n n i s h  m e n  
a g e d  65 to 84  years ,  o n e  in E a s t e r n  and  the  o t h e r  in S o u t h -  
w e s t e r n  F i n l a n d ,  and  w h e t h e r  s u c h  i n f o r m a t i o n  pe r s i t s  af -  
t e r  o t h e r  r i sk  f a c t o r  t ra i t s  are  c o n s i d e r e d ?  
Materials and methods 
Sample 
The Seven Countries Study was initiated in the late t950s to study 
variation in cardiovascular disease mortality and morbidity and re- 
lated risk factor levels among countries, including Finland (Keys 
1970; Pekkanen 1987). The original Finnish cohorts (n = 1711) 
consisted of all men born between 1900 and 1919 in two geographi- 
cally defined rural areas, one in Eastern and the other in South- 
western Finland. Of these, 823 were from the Eastern cohort and 
888 from the Southwestern cohort. In 1984, when baseline assays 
for the current study were performed, 766 of the 1711 men were 65 
to 84 years old and were still alive. Of these eligible men, 716 
(93%) participated in the medical examination. The reasons for the 
nonparticipation of 50 individuals included length of travel dis- 
tance, recent myocardial infarct, severe rheumatic fever, and re- 
fusal to participate. Knowledge about apoE phenotype was avail- 
able for 666 (87%) men. Of the 50 nonparticipants and 50 partici- 
pating subjects whose apoE phenotype was not known at baseline, 
a total of 45 died during the follow-up period. 
At the time of the follow-up survey in 1989, of the 666 men 
whose apoE phenotype was known at baseline, 468 were still alive 
and 198 had died. Death certificates and hospital records were ob- 
tained for all the deceased men and the cause of death was coded 
by one of the authors (J.P.) according to fixed criteria (Keys et al. 
1967). The coding was performed without knowledge about the in- 
dividual 's  apoE genotype. All participants gave their informed 
consent before their inclusion in the study. 
Study protocol 
Both baseline and follow-up surveys of each geographic region 
were conducted during the same month of the year, October in the 
East and November in the Southwest. Complete details of the 
study protocols of the 1984 baseline survey and the follow-up sur- 
vey in 1989 are given elsewhere (Nissinen et al. 1986, 1993). All 
participants fasted at least 4 h before their visit at the clinic (mean 
fasting time was 13 h, standard deviation 5 h; 75% of the partici- 
pants fasted 8 h or more). At the clinic, blood samples were drawn 
from the antecubital vein for laboratory analyses. Body weight was 
measured to the nearest 0.1 kg in light undergarments. Height was 
measured only in 1959, when the men were first seen in connec- 
tion with the Seven Countries Study. This height was used to cal- 
culate body mass index (BMI, kg/m2), an index of body size used 
in the current analyses. 
Smoking status was assessed using a standard questionnaire 
(Keys et al. 1967). Participants were classified into the following 
two categories: smokers of cigarettes, cigars or pipes, and non- 
smokers. Participants who had quit smoking less than 1 year be- 
fore the survey were classified as smokers. 
Blood pressure was measured by a trained nurse. After at least 
a 5-min rest at the end of clinical examination, two successive 
readings were taken from the right arm using a mercury manome- 
ter with a 12 cm by 33.5 cm cuff. Readings were taken to the near- 
est 2 mmHg and complete disappearance of the fifth phase of Ko- 
rotkoff sounds was recorded as the diastolic pressure. We used the 
mean values of the two readings for the analyses presented in this 
study. 
Laboratory measurements 
Total and HDL cholesterol concentrations were assayed using an 
enzymatic method (Monotest, new, Boehringer Mannheim, Mann- 
heim, Germany) and an Olli C3000 photometer (Kone Oy, Fin- 
land). Total cholesterol was deternlined from a fresh serum sample 
(Kostner 1976). HDL cholesterol was measured after precipitation 
of very low density lipoprotein (VLDL) and low density lipopro- 
tein (LDL) particles with dextran magnesium chloride (Kostner 
1976). ApoE phenotypes were determined using sera stored at 
- 2 0 ° C  until utilized in 1992. ApoE phenotyping was carried out 
according to a modification of the method of Havekes (Ehnholm et 
al. 1986; Havekes et al. 1987), which was based on isoelectric fo- 
cusing of delipidated serum followed by immunoblotting using 
rabbit anti-human apoE antiserum. ApoE genotypes were inferred 
from the isoform phenotypes. 
Statistical analysis 
Baseline differences between the men who died from CHD and 
those who did not die from CHD during the 5-year follow-up pe- 
riod were tested for statistical significance using the analysis of 
variance for quantitative traits and Z 2 statistics for categorical vari- 
ables. 
A three-stage model-building strategy and hypothesis-testing 
procedure was used to estimate the nature of the association be- 
tween variation in CHD death probability and variation m CHD 
risk factor levels and genotypic variation in apoE. First, a logistic 
regression analysis was employed to assess whether any of the 
CHD risk factor traits, or information about the apoE genotype, 
predicted CHD mortality when they were considered one at a time 
in the model, separately for the Eastern and the Southwestern co- 
horts. The CHD risk factor traits considered were age, BM1, sys- 
tolic and diastolic blood pressure, total and HDL cholesterol lev- 
els, and smoking status. The effect of each apoE genotype was 
modeled by coding design variables in such a way that the e3/3 
genotype represented the reference class. Twice the logarithm of 
the ratio of the maximum value of the likelihood of a model with 
(complete model) and without (reduced model) a particular trait 
was taken to be distributed approximately as a X 2 for the test of 
whether its contribution was statistically significant. 
The antilogarithm of the difference between the estimated log- 
its computed at two different levels of a risk factor trait gives an 
estimate of the ratio of the odds of dying from CHD for individu- 
als at the two levels of the trait. In this study the odds ratio tor each 
quantitative trait was calculated for a one standard deviation in- 
crease above its mean value, separately for the Eastern and the 
Southwestern cohorts. 
In the second stage, a parsimonious subset of the risk factor 
traits, ignoring the apoE genotype, was selected, separately lbr the 
Eastern and the Southwestern cohorts. Initially any trait whose 
log-likelihood ratio test in the first stage gave a type I error proba- 
bility less than 0.25 was considered in the model in the cohort 
where this result was found. This relatively high probability level 
was selected because use of a more traditional test criterion (such 
as 0.05) at this point often fails to identify traits that can become 
important predictors of outcome only when they are considered in 
a multivariable prediction model (Hosmer and Lemeshow 1989). 
The importance of each variable, its second-order term, or any of 
their pairwise interactions in the multivariable model, was verified 
by the stepwise backward elimination procedure. Removal of a 
variable was based on the value of the residual Z 2. The level of sta- 
tistical significance was taken to be P < 0.05 for the elimination of 
a variable from the final model. A Hosmer-Lemeshow approach, 
which partitions the distribution of predicted probabilities into 
deciles, and subsequently sums the difference between the ob- 
served proportion of the men who died from CHD and the average 
predicted probability for subjects in each decile (Hosmer and 
Lemeshow 1989), was used to assess goodness-of-fit of the final 
model. This sum, denoted here as ~HL, is distributed approximate- 
ly as a ~2 with 8 degrees of freedom (df). Hence, (~HL greater than 
15.508 was taken as an indication of lack-of-fit at the P < 0.05 
level of statistical significance. The evaluation for goodness-of-fit 
was informative because the log-likelihood ratio statistic used in 
the model building process is based on the relative comparison of 
two fitted models, not on the absolute comparison of the probabil- 
ities predicted by the proposed model with the observed outcomes. 
Somer's D was also employed to explore effectiveness of the pro- 
posed model to discriminate between the men who died from CHD 
and those who did not die from CHD. The value of Somer's D 
varies between 0 and 1, where a value of 1 indicated perfect abil- 
ity of the proposed model to discriminate between the men who 
died from CHD and those who did not die from CHD. 
In the third stage, a multivariable logistic regression analysis 
was employed to assess whether addition of the apoE genotype in- 
formation to the model established in the second stage improved 
the prediction, separately for the Eastern and the Southwestern co- 
hort. A log-likelihood ratio test, which compares the maximum 
likelihood of a multivariable model that includes both information 
about apoE genotype and the parsimonious subset of other risk fac- 
tor traits (complete model) and maximum likelihood of the model 
that includes only the other traits (reduced model), was used to 
judge whether the improvement in prediction attributable to the 
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apoE genotype was statistically significant. The degrees of free- 
dom for the )~2 statistic associated with this test are one less than 
the number of apoE genotypes considered in the analysis. 
All statistical analyses were performed with the SAS statistical 
software package (SAS 1985). Statistical significance was taken to 
be P < 0.05 unless otherwise noted. 
Results 
Description of  the cohorts 
The Eastern cohort included 281 men  and the Southwest- 
ern cohort 344 men for whom knowledge about both apoE 
genotype and all risk factor trait levels were available. Of  
them, 26 (9.3% of the sample) in the Eastern cohort and 
40 (11.6% of the sample) in the Southwestern cohort died 
from CHD during the 5-year fol low-up period. Hetero- 
geneity of  the relative 5-year CHD mortali ty between the 
Eastern and the Southwestern cohorts was not statistically 
significant X 2 = 0.38, d f  = 1, P = 0.54). 
The fol lowing observations were statistically signifi- 
cant  at the P < 0.05 level of probabili ty:  the men  who died 
from CHD in the Eastern cohort were older, had lower av- 
erage HDL cholesterol levels, and used antihypertensive 
drugs more often than those who did not die from CHD 
(Table 1). In the Southwestern cohort the men who died 
from CHD were significantly older, had significantly 
higher average total cholesterol levels, had significantly 
Table 1 Baseline characteris- 
tics by cohort and coronary 
heart disease (CHD) death sta- 
tus after 5 years follow-up 
*P < 0.05, compared subjects 
who had died from CHD and 
those who had not died from 
CHD within a sample 
Trait Eastern cohort and CHD death 
Yes No 
(n = 26) (n = 255) 
Southwestern cohort and 
CHD death 
Yes No 
(n = 40) (n = 304) 
Age (years) 
Mean (SD) 73.7 (4.7)* 71.5 (4.8) 75.2 (5.8)* 73.0 (5,2) 
Anthropometry 
BMI (kg/m 2) 
Mean (SD) 26.3 (4.2) 25.3 (4.0) 26.4 (3.9) 25.9 (4.2) 
Obese (%) 36 34 45 39 
Serum cholesterol 
Total (mmol/1) 
Mean (SD) 6,1 (I.6) 6.2 (1.3) 6.5 (1.7)* 6.0 (1.2) 
HDL (mmol/1) 
Mean (SD) 1.1 (0.4)* 1.2 (0.3) 1.1 (0.3)* 1.2 (0.3) 
Blood pressure 
Systolic (mmHg) 
Mean (SD) 142 (25) 150 (22) 159 (24) 157 (22) 
Diastolic (mmHg) 
Mean (SD) 83 (12) 85 (11) 89 (10) 89 (11) 
Antihypertensive 
drugs (%) 54* 31 38 33 
Hypertensive (%) 64 52 69 66 
Smoking status 
Current (%) 19 23 31 * 17 
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Table 2 The ApoE genotypes 
by cohort and CHD death sta- 
tus alter 5 years follow-up :~ 
a Fisher's exact test was em- Yes No 
ployed because expected cell 
sizes were less than five in Genotype 
more than 25% of the cells, e2/2 0 (0) 
The relative frequencies of ~;2/3 l (3.9) 
genotypes were heterogeneous e3/3 15 (57.7) 
between the men who had died 
from CHD and those who had e3/4 7 (26,9) 
not died from CHD in the ~2/4 2 (7.7) 
Eastern sample at P = 0.104 e4/4 l (3.8) 
and in the Southwestern sam- All 26 (100.0) 
pie at P = 0.014 
Eastern cohort and CHD death, 
number (%) 
Southwestern cohort and 
CHD death, number (%) 
Yes No 
0 (0) 0 (0) 0 (0) 
15 (5.9) 1 (2.5) 26 (8.5) 
178 (69.8) 16 (40,0) 180 (59.2) 
56 (21.9) 2l (52.5) 86 (28.3) 
4 (1.6) 2 (5.0) 12 (4.0) 
2 (0.8) 0 (0) 0 (0) 
255 (100.0) 40 (100.0) 304 (100.0) 
Table 3 Predictors of CHD death among elderly Finnish men in a 
univariable logistic regression analysis, separately for the Eastern 
and the Southwestern cohort (X2tmR = Log-likelihood ratio )C-, dr= 1 
for all tests, 95% CI = 95% confidence interval, BMI = body mass 
index (kg/m2), HDL = high density lipoprotein cholesterol; Re,q, 
coef= regression coefficient; SE = standard error) 
Trait Eastern cohort 
Reg )2LHR P Odds 95% CI 
coef SE ratio 
Southwestern cohort 
Reg g2Lu R P Odds 95% CI 
coef SE ratio 
Age 0.08 0.(14 3,96 0.05 1,47 (1.00, 2.14) 
Anthropomet 0' 
BMI 0.06 0.05 1.55 0.21 1.27 (0.86, 1.89) 
Serum cholesterol 
Total 0.03 0.16 0.03 0.86 1,04 (0.69, 1.57) 
HDL -1.28 0.71 3.61 0.06 1.54 (0.96, 2.46) 
Blood pressure 
Systolic -0.01 0.01 1.43 0.23 0.80 (0.52, 1.24) 
Diastolic -0.01 0.02 0.36 0.55 0.90 (0.59, 1.37) 
Smoking status 
No 0 - 0.17 0.68 1 - 
Yes -0.21 0.52 - - 0.8t (0.29, 2.25) 
Apo E genotype 
e3/3 0 - 4.96 0.18 1 
e2/3 -0.23 1.07 - 0.79 (0.10, 6.40) 
~2/4 ~' 1,78 0.76 - - 5.93 ( 1.35, 26.1 ) 
e3/4 0.39 0.48 - - 1.48 (0.58, 3.82) 
0.08 0.03 6.02 0.01 1.53 (1.12, 2.08) 
0.03 0.04 0.49 0.48 1.13 (0.82; 1.55) 
0.37 0.13 7.82 0.01 1.56 (1.14, 2.12) 
-- 1.42 0.61 5.52 0.01 1.57 (1.07, 2.29) 
0.01 0.01 0.45 0.50 1.24 (0.81, 1.91) 
-0.01 0.02 0.04 0.84 0.90 (0.59, 1.37) 
0 - 5.08 0.02 I - 
0.87 0,37 - - 2.39 ( I. 15, 4.95) 
0 - 10.46 0.02 1 - 
-0.84 1.05 - - 0.43 (0.06, 3.40) 
0.63 0.81 - - 1.88 (0.39, 9.12) 
1.01 0.36 - 2.75 ( 1.37, 5.53) 
"e4/4 was combined with e2/4 in the Eastern cohort; e4/4 was not observed in the Southwestern cohort 
l o w e r  a v e r a g e  H D L  cho les t e ro l  l eve ls ,  and w e r e  current  
smoke r s  s ign i f i can t ly  m o r e  of ten  than the m e n  o f  this co-  
hort  w h o  did not  die  f r o m  C H D  (Table  1). 
The  re la t ive  a p o E  g e n o t y p e  f r e q u e n c i e s  in the Eas te rn  
cohor t  w e r e  h e t e r o g e n e o u s  b e t w e e n  the m e n  w h o  d ied  
f rom C H D  and those  w h o  did  not  die  f rom C H D  at the P 
= 0 .10 level  o f  probabi l i ty .  The  ~3/3 was  the mos t  fre-  
quen t  g e n o t y p e  and the E3/4 was  the nex t  in both  o f  these  
strata. R e l a t i v e  f r e q u e n c i e s  o f  the ~3/4 g e n o t y p e  and the 
o the r  ~;4 a l l e l e - con t a in ing  geno types ,  ~2/4 and  ~4/4, were  
h i g h e r  a m o n g  the  m e n  w h o  d ied  f r o m  C H D  (26 .9%,  
7 .7%,  and 3 .8%,  r e spec t ive ly )  than a m o n g  those  w h o  did 
not  die  f rom C H D  (21.9%,  1.6%, and 0 .8%,  r e spec t ive ly )  
w he rea s  re la t ive  f r e q u e n c y  o f  the ~3/3 g e n o t y p e  was  
l o w e r  a m o n g  those  w h o  d ied  f rom C H D  (57 .7%)  than 
a m o n g  those  w h o  did  not  d ie  f rom C H D  (69.8%).  T h e  
least  f r equen t  e4 /4  and e2 /4  g e n o t y p e s  were ,  h o w e v e r ,  
r eco rded  on ly  in three m e n  w h o  d ied  f rom C H D  and six 
m e n  w h o  did not  die  f r o m  C H D  in the Eas te rn  cohor t .  
T h e  re la t ive  a p o E  g e n o t y p e  f r e q u e n c i e s  in the South-  
wes te rn  cohor t  w e r e  h e t e r o g e n e o u s  b e t w e e n  the m e n  w h o  
d ied  f r o m  C H D  and those  w h o  did  not  die  f rom C H D  at 
the P = 0.01 level  o f  p robab i l i ty  (Table  2). T h e  e3 /4  was  
the m o s t  f r equen t  g e n o t y p e  (52 .5%)  and the ~3/3 the next  
m o s t  f r equen t  g e n o t y p e  (40 .0%)  a m o n g  the m e n  w h o  d ied  
f r o m  C H D ,  whe rea s  in the m e n  w h o  did  not  die  f rom the 
C H D  the E3/3 was the mos t  f requen t  geno type  (59 .2%)  and 
the e3/4  the next  mos t  f requen t  geno type  (28.3%).  The  two 
least  f r equen t  g e n o t y p e s  in the S o u t h w e s t e r n  cohor t  were  
E2/3 and ~2/4. T h e s e  g e n o t y p e s  w e r e  r eco rded  in less than 
5% o f  the m e n  w h o  d ied  f rom C H D  and less than 10% of  
the m e n  w h o  did  not  die  f rom C H D .  N o  ind iv idua l s  wi th  
the c4/4  g e n o t y p e  w e r e  r eco rded  in the S o u t h w e s t e r n  co-  
hort.  The  ~2/2 g e n o t y p e  was  not  r eco rded  in e i ther  cohor t .  
Univariable analysis 
Age and HDL cholesterol were the only traits in the East- 
ern cohort that were significant predictors of  CHD death 
at the P < 0.06 level of  probability when considered sepa- 
rately in the logistic regression model (Table 3), Further- 
more, BMI and systolic blood pressure fall below the P < 
0.25 level of  significance, indicating that these traits 
should be considered as candidates in the subsequent mul- 
tivariable logistic regression analysis in the Eastern co- 
hort. In the Southwestern cohort, age, total and HDL cho- 
lesterol levels, and smoking status were each significant 
predictors of  CHD death at the P < 0.05 level of statistical 
significance. No other predictors reach the P < 0.25 level 
of  probability in the Southwestern cohort. 
Variation among the observed apoE genotypes con- 
tributed to the prediction of the CHD death at the P = 0.18 
level of  statistical significance in the Eastern cohort when 
variation in other risk factor traits was ignored. In the 
Southwestern cohort the contribution of genotypic varia- 
tion was significant at the P = 0.02 level of  probability. 
Because the e4/4 genotype was recorded only in three par- 
ticipants in the Eastern cohort, the carriers of the e4/4 
were combined with the carriers of the e2/4 genotypes for 
the logistic regression analysis in the Eastern cohort. 
The odds of  CHD death for those with the rare e2/4 
and the e4/4 genotypes in the Eastern cohort was about six 
times higher than odds of CHD death among the carriers 
of  the reference e3/3 genotype (Table 3). The odds of 
CHD death for those with the e3/4 genotype was about 
three times higher than the odds of the carriers of  the ref- 
erence ~3/3 genotype in the Southwestern cohort. 
Multivariable models ignoring apoE genotypes 
When all putative risk factor traits, other than the apoE 
genotypes, that reached the P < 0.25 test criterion in uni- 
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variable analyses were considered, the stepwise backward 
elimination process identified HDL cholesterol and (HDL 
cholesterol) 2 but not age, BMI, nor systolic blood pressure 
as the statistically significant predictors of  CHD mortality 
at the P < 0.05 level of  probability in the Eastern cohort. 
In contrast, in the Southwestern cohort all the risk factor 
traits that were significant predictors in univariable mod- 
els were also detected as significant predictors in a multi- 
variable model of the data. No statistically significant in- 
teractions between any of the risk factor traits were de- 
tected in either cohort at the P < 0.05 level of  probability 
(results not shown). Hence, the final multivariable logistic 
regression model, when apoE genotypic information was 
ignored, was: CHD death probability = 2.74-7.17 (HDL 
cholesterol) + 2.27 (HDL cholesterol) 2 in the Eastern co- 
hort and CHD death probability = -11.25 + 0.11 (age) + 
0.47 (total cholesterol) - 1.52 (HDL cholesterol) + 0.87 
(smoking status) in the Southwestern cohort. In both co- 
horts the CHL value of the Hosmer-Lemeshow goodness- 
of-fit statistics was below the critical level (2.00 vs 11.07 
in the Eastern cohort and 9.33 vs 15.51 in the Southwest- 
ern cohort), indicating that the models fit the observed 
outcomes acceptably well. Even so, relatively low values 
of  the Somer 's  D (0.38 in the Eastern cohort and 0.47 in 
the Southwestern cohort) indicate only moderate ability of  
the models to discriminate between the men who died 
from CHD and those who did not die from CHD during 
the 5-year follow-up. 
Multivariable models including apoE genotypes 
When information about the apoE genotypic variation 
was entered into a model that already included the se- 
lected set of other CHD risk factor traits, it resulted in a 
marginally significant improvement in the ability to pre- 
dict CHD death both in the Eastern cohort (~2LH R = 6.13, 
Table 4 Predictors of CHD death among elderly Finnish men in a multivariabte logistic regression analysis when both Apo E genotypic 
information and the parsimonious set of other CHD risk factor traits are considered, separately for the Eastern and the Southwestern cohort 
Trait Eastem cohort Southwestern cohort 
Partial SE Partial 95% CI 
reg coef odds ratio 
Partial SE Partial 95% CI 
reg coef odds ratio 
Age . . . .  
Serum cholesterol 
Total . . . .  
HDL -8.06 2.77 - - 
(HDL) 2 2.56 0.98 2.16 - 
Smoking status 
N O  . . . .  
Yes . . . .  
Apo E genotype 
e3/3 0 - 1 
e2/3 -0.30 1.10 0.75 
a2/4 a 2.04 0.78 7.69 




0.11 0.04 1.79 (1.17, 2.72) 
0.42 0.15 1.66 (1.16, 2.34) 
-1.39 0.65 1.55 (1.03, 2.34) 
0 - -  1 - -  
0.84 0.40 2.29 (1.05, 5.00) 
0 - -  1 - -  
-0.42 1.08 0.66 (0.08, 1.70) 
0.37 0.86 1.45 (0.28, 7.85) 
0.89 0.38 2.44 (1.16, 5.10) 
"e4/4 was combined with e2/4 in the Eastern cohort; e4/4 was not observed in the Southwestern cohort 
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dr= 3, P = 0.10) and in the Southwestern cohort (•2LH R ---- 
6.25, df  = 3, P = 0.10). The (~uL value of the Hosmer- 
Lemeshow goodness-of-fit statistics increased from 2.00 
to 2.81 in the Eastern cohort and decreased from 9.33 to 
7.47 in the Southwestern cohort. The value of the Somer's 
D increased slightly in both cohorts (from 0.38 to 0.46 in 
the Eastern cohort and from 0.47 to 0.50 in the South- 
western cohort). 
The estimates of partial regression coefficients ob- 
tained in the multivariable logistic regression analysis 
where both the selected CHD risk factor traits and the 
apoE genotypes were considered are given in Table 4, 
separately for the Eastern and the Southwestern cohorts. 
In both cohorts, addition of the apoE genotype informa- 
tion to the multivariable logistic regression model resulted 
in only minor changes in the estimates of the regression 
coefficients when compared to the respective estimates in 
the model where apoE genotypic information was ig- 
nored. Similarly, there were only minor changes in the es- 
timates of partial regression coefficients for different apoE 
genotpyes in the multivariable model when compared 
with the univariable model where apoE genotypic infor- 
mation was the only variable considered. 
Discussion 
Coronary heart disease accounted for 30% to 40% of the 
deaths recorded during the 5-year follow-up period in the 
two cohorts of elderly Finnish men considered in this 
study. Of the known CHD risk factor traits, age and HDL 
cholesterol were predictors of CHD death in both cohorts. 
However, age was a significant predictor only in the 
Southwestern cohort after effects of other risk factor traits 
were considered. Similarly, total cholesterol and smoking 
status were predictors only in the Southwestern cohort. 
The ranges of variability of these risk factor traits at base- 
line were approximately the same as the ranges reported 
in other studies of elderly men (Barrett-Connor et al. 
1984; Jacobsen et al. 1992; Stavenow et al. 1990). These 
findings are consistent with earlier reports that CHD risk 
factor traits that are identified as predictors in middle- 
aged men are predictors also in elderly men (Assmann 
and Schulte 1989; Barrett-Connor et al. 1984; Harris et al. 
1988). The combinations of the CHD risk factors that 
were identified as predictors in the Eastern and South- 
western cohorts in this study differ, however, from the 
combinations reported to be present in these cohorts 20 
years earlier (Heti6vaara et al. 1981; Karvonen et al. 
1970). In the earlier studies, when the men were in their 
middle ages, total cholesterol, blood pressure and smok- 
ing status were significant predictors of CHD events in 
both cohorts (Heli6vaara et al. 198l; Karvonen et al. 
1970). This age related change in the predictive power of 
the CHD risk factor traits may reflect (1) biochemical and 
physiological changes that are associated with the aging 
process per se that lead to an altered atherogenic risk fac- 
tor profile, (2) selective mortality against high risk indi- 
viduals in their early adulthood, or (3) age-related 
changes in the environment defined by physical activity, 
diet, other diseases, and drug therapy. 
Baseline distributions of the apoE genotypes differed 
significantly between the Eastern and Southwestern co- 
horts ()~2HL R = 14.93, d f=  4, P = 0.005). An excess of the 
82/3, the 83/4, and the 82/4 genotypes was recorded in the 
Southwestern cohort compared with the Eastern cohort 
(Stengfird et al. 1995). This heterogeneity of the apoE 
genotypic distribution may reflect selective mortality 
against the high risk 84 allele containing genotypes in the 
Eastern cohort in the past. An earlier observation that 
apoE genotype frequencies did not differ significantly be- 
tween children born in Eastern and Southwestern Finland 
(Lehtim~iki et al. 1990) supports the selective mortality 
hypothesis. 
Our longitudinal 5-year follow-up study demonstrates 
that apoE genotypic variation is a statistically significant 
predictor of variation in risk of CHD death in the South- 
western cohort when contribution of other risk factor 
traits are ignored. The 83/4 genotype was, however, the 
only genotype in this cohort that was associated with sig- 
nificantly increased odds of CHD death (95% confidence 
interval did not include one) as compared with odds for 
the reference 83/3 genotype. In the Eastern cohort the con- 
tribution of apoE ganotypic variation to prediction of vari- 
ation in risk of CHD death was only marginally signifi- 
cant (P = 0.18). The odds of CHD death among carriers of 
the combined groups of the rare 82/4 and the e4/4 geno- 
types in the Eastern cohort was, however, significantly 
higher than the odds for the carriers of the reference 83/3 
genotype. The latter finding suggests that individual geno- 
types may confer risk information that is not detected by 
the global test of the contribution of all the observed geno- 
types. In this context we emphasize that we did not record 
the 82/2 genotype in either cohort and the 84/4 was 
recorded only in the Eastern cohort. Inferences based on 
samples with all the apoE genotypes represented may dit- 
fer from the inferences suggested by the results obtained 
in this study. Furthermore, differences between the geno- 
types that were identified as predictors in the Eastern and 
the Southwestern cohorts emphasize that genotypic infor- 
mation may be expected to be context dependent where 
context is defined by at least (1) the mortality history of 
the population, (2) geographically defined environmental 
factors, or (3) the evolutionary history of the background 
genotypes that influence risk of CHD. 
The odds of CHD death among the carriers of the 82/3 
genotype tended to be 30% to 50% lower than the odds of 
the carriers of the reference genotype 83/3 in both cohorts. 
This finding is consistent with a hypothesis that the 82 al- 
lele confers some protection against CHD (Davignon 
1993). On the other hand, our finding is inconsistent with 
observations that the 82 allele confers atherogenic poten- 
tial in some populations (Davignon 1993; Andrade et at. 
1995). The lowered estimates of the odds were not statis- 
tically significant in either cohort in this study. Any infer- 
ences about the atherogenic or antiatherogenic potential 
of the 82/3 genotype based on our results must, however, 
be tentative because only 3 (1 in the Eastern cohort and 2 
in the Southwestern cohort) CHD deaths were recorded 
for this genotype class during the 5-year follow-up, i.e., 
the result may be a type II error. 
The contribution of any genotypic variation to the ini- 
tiation, progression, and clinical manifestation of athero- 
sclerotic process must be translated through variation in 
and covariation between biochemical and physiological 
traits that determine variation in risk of disease (Ferran- 
nini 1991; Sing et al. 1994). The complex pathophysiol- 
ogy of atherosclerosis dictates that the contribution of 
genotypic variation to prediction of any CHD outcome, 
such as CHD death in this study, may not persist when 
variation in all traits involved in linking genome variation 
with variation in risk of disease are considered. Our find- 
ing that addition of the information on apoE genotypic 
variation to models that already include a selected subset 
of other risk factor traits improved the prediction of CHD 
death at the P = 0.10 level of statistical significance sug- 
gests that this null hypothesis does not hold when apoE 
genotypic variation is considered in these two cohorts of 
elderly Finnish men. Furthermore, the carriers of the rare 
e2/4 and the e4/4 genotypes in the Eastern cohort and the 
carriers of the e3/4 genotype in the Southwestern cohort 
were associated with an odds of CHD death significantly 
higher than the odds for the reference e3/3 genotype in 
this multivariable model. This latter observation indicates 
that although genotypic variation of apoE improves the 
ability in the prediction only marginally, individual apoE 
genotypes can confer risk information that remains highly 
significant after other risk factor traits are considered. 
Importance of a risk factor, such as a high-risk apoE 
genotype, to the public health in the population at large is 
related to both the relative risk and the proportion of the 
population exposed to this particular risk factor (Kahn 
1983). Attributable risk is an epidemiological concept that 
reflects the fraction of all cases that are associated with 
the proposed risk factor. An estimate of attributable risk 
of the CHD death for the rare high risk ~2/4 and e4/4 
genotypes was 0.16 in the Eastern cohort, while the attrib- 
utable risk for the e3/4 genotype in Southwestern cohort 
was 0.32. Estimates of the odds ratio and proportion of the 
carriers for each genotype were used for the attributable 
risk computations. These findings suggest that 16% of the 
CHD deaths in the Eastern cohort and 32% in the South- 
western cohort were associated with these high risk geno- 
types. In this context we want to emphasize, however, that 
attributable risk only summarizes the proportion of CHD 
deaths associated with the risk factor. 
A relatively small fraction (20% to 30%) of the carriers 
of  the high-risk genotypes, the rare e2/4 and ~4/4 geno- 
types in the Eastern cohort and the e3/4 genotype in the 
Southwestern cohort, died from CHD during the 5-year 
follow-up period. A considerable proportion of the men 
who died from CHD did not carry these high-risk geno- 
types. Of the non-high-risk genotypes, the common e3/3 
genotype accounted for 60% of the CHD deaths in the 
Eastern cohort and 40% in the Southwestern cohort. These 
findings are consistent with the complex pathophysiology 
of CHD (Ferrannini 1991 ; Sing et al. 1994). A consequence 
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of this complex pathophysiology is that the mapping func- 
tion between variation in a single gene, or variation in any 
single environmental factor, and variation in diesease risk 
is not simple (Ferrannini 1991; Sing et al. 1994; Wahlsten 
1990; Weiss 1993). From the genetic point of view the im- 
plication is that an individual's genome type determines 
the way he or she reacts to a particular history of expo- 
sures to environmental factors (Cooper and Rotimi 1994; 
Lewontin 1974; Wahlsten 1990). Our study serves to fur- 
ther convince that none of the apoE genotypes cause dis- 
ease; genotypic variation in apoE can only contribute to 
interindividual variation in susceptibility to CHD. 
In conclusion, the results of this 5-year follow-up study 
demonstrate that conventional CHD risk factor traits such 
as age, total and HDL cholesterol and smoking status, and 
variations in the apoE gene, confer information about risk 
of CHD death in elderly Finnish men. The risk informa- 
tion from apoE genotypes persisted after variation in other 
risk factor traits was considered. Utility of a particular 
risk factor trait or a particular apoE genotype as a predic- 
tor of future CHD death varied, however, among subdivi- 
sions of the Finnish population defined by geographical 
area of residence. This finding is consistent with earlier 
findings that have demonstrated the complexity of the 
mapping function between variation in risk factor levels 
and variation in risk of  CHD. Heterogeneity of predictors 
among subdivisions of the elderly Finnish population brings 
into question the applicability of the inferences from this 
study to other subdivisions of the Finnish population de- 
fined by age and gender, and to other populations with 
different risk factor profiles, with exposures to different 
environmental histories or with different evolutionary his- 
tories for the genetic background. It is most likely that 
each population represents a different combination of  ge- 
netic and environmental factors that interact to determine 
susceptibility to CHD. 
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